The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China

Expert Opin Drug Saf. 2019 Jan;18(1):51-58. doi: 10.1080/14740338.2019.1559812. Epub 2018 Dec 21.

Abstract

Background: High-quality adverse drug reaction (ADR) reports are essential for conducting drug safety monitoring in pharmacovigilance. The study aim was to assess the current quality of ADR reports in western China, and to identify problems with ADR report quality.

Research design and methods: A sample of 1139 reports received by the Shaanxi ADR Monitoring Center from January 2015 to December 2017 was selected. ADR report quality was evaluated using an ADR report quality evaluation system.

Results: None of the reports were rated as excellent and 1.40% (n = 16) as good. Report quality was better for new and serious reports than for general reports. Medical institutions generated higher quality reports than pharmaceutical manufacturers. Nurses generated higher quality reports than doctors, pharmacists, and other professionals. Reporters of different occupations showed significant differences in the quality of the indicators Reporting time limit, Intervention ADR time, ADR termination time, ADR intervention measures, Original disease, and Cause of medication (P = 0.000).

Conclusions: The ADR data quality was poor in western China, and of lower quality than reported data from previous research in other regions. Improvements in the quality and availability of ADR reports are urgently needed.

Keywords: Spontaneous reporting; adverse drug reactions; drug safety; pharmacovigilance; quality assessment.

MeSH terms

  • Adolescent
  • Adult
  • Adverse Drug Reaction Reporting Systems / standards
  • Adverse Drug Reaction Reporting Systems / statistics & numerical data*
  • Aged
  • Aged, 80 and over
  • Child
  • Child, Preschool
  • China / epidemiology
  • Data Accuracy
  • Drug-Related Side Effects and Adverse Reactions / epidemiology*
  • Health Personnel / statistics & numerical data*
  • Humans
  • Infant
  • Middle Aged
  • Pharmacovigilance*
  • Young Adult